There is a very public conversation about drug prices and costs occurring in the United States presently, but important parts of the discussion are obscured by the complexities and lack of transparency of the current pricing system.
Most patients' costs are low, their share of costs is going down, and their costs are also trending down on average. However, specific patient groups are facing prices that are rising and unaffordable to them, with consequences for their health and their financial wellbeing.
Join IQVIA Institute Research Director, Michael Kleinrock, as he provides context and clarity on the pricing of prescription medicines and the consequences that result for patients. Ask Michael questions live about the recently published IQVIA Institute Medicine Spending and Affordability in the U.S. report.
Webinar discussion topics will include